<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055648</url>
  </required_header>
  <id_info>
    <org_study_id>DCPT101008134</org_study_id>
    <nct_id>NCT05055648</nct_id>
  </id_info>
  <brief_title>PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy (PROTECT) A Multicenter International Randomized Phase III Study of Neoadjuvant Proton Versus Photon Chemoradiotherapy in Locally Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Ziekenhuis Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CNAO National Center of Oncological Hadrontherapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agenzia Nazionale per i Servizi Sanitari Regionali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paul Scherrer Institut, Center for Proton Therapy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HollandPTC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>IBA worldwide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Varian- A Siemens Healthineer Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose&#xD;
      reductions to sensitive, normal tissues will result in lower rates of treatment-related&#xD;
      pulmonary complications in esophageal cancer compared to standard photon therapy (XT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTECT is a unblinded international multicenter randomized phase III study for patients with&#xD;
      operable EC or EGC receiving nCXT (standard of care) or nCPT (intervention). The study will&#xD;
      be open-label for the patient and the treating physician.&#xD;
&#xD;
      The radiation dose is either 41.4 Gy in 23 fractions, five fractions per week or 50.4 Gy in&#xD;
      28 fractions, five fractions per week. Prior to trial opening, each proton center will&#xD;
      determine a single dose regimen for all patients treated in that specific proton center and&#xD;
      its assigned photon centers.&#xD;
&#xD;
      The protocol prescribes that all referring centers will use the same chemotherapy regimen,&#xD;
      which is weekly carboplatin (AUC 2), and paclitaxel (50 mg/m2), five cycles, irrespective of&#xD;
      choice of dose regimen. Chemotherapy is a non-investigational drug.&#xD;
&#xD;
      Prior to referral to any proton therapy center, patients will be randomed (1:1) to either&#xD;
      nCXT or nCPT. Only patients randomized to the PT arm will be referred to a PT center.&#xD;
      Randomization will be performed centrally using an online 24-hour web-based system maintained&#xD;
      by the Clinical Trial Office at Aarhus University Hospital, ensuring allocation concealment&#xD;
      to the clinical investigators. The method of randomization will be stratified permuted blocks&#xD;
      of size 4 and 6 (selected randomly) with the following strata:&#xD;
&#xD;
        -  Histopathology (non-squamous vs squamous cell carcinoma)&#xD;
&#xD;
        -  Planned surgical technique (open versus minimal invasive/robotic or hybrid)&#xD;
&#xD;
        -  Proton center and sites assigned to this center (which will deliver the nCXT)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label, non-blinded, international multicenter, randomized phase III study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary complications</measure>
    <time_frame>from randomization until 90 days after surgery</time_frame>
    <description>Incidence of pulmonary complications during and following nCPT or nCXT and surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early toxicity</measure>
    <time_frame>from start of nCPT or nCXT until surgery</time_frame>
    <description>Predefined items ≥ grade 2 scored by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Predefined items ≥ grade 2 scored by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>from surgery until 90 days after surgery</time_frame>
    <description>Predefined items scored by Clavien-Dindo and Comprehensive Complications Index (CCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events (MACE)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Predefined cardiovascular events scored by MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcome measures</measure>
    <time_frame>up to 5 years</time_frame>
    <description>EORTC quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with trimodality treatment</measure>
    <time_frame>3 months</time_frame>
    <description>The proportion of patients complying with trimodality treatment in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>tumor regression grade for the primary tumor scored according to Mandard score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of loco-regional failure</measure>
    <time_frame>from date of randomization up to 5 years</time_frame>
    <description>Locoregional failure evaluated according to RECIST with all failures within the irradiated volume counting as events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of failure</measure>
    <time_frame>up to 5 years</time_frame>
    <description>First site of failure will be divided in loco-regional lymph node failures, loco-regional failures in anastomosis, and distant extra-cranial and intra-cranial failures. All loco-regional failures will be divided in failures inside and outside the treatment volume, which is defined to be within the specified treatment dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Disease control evaluated according to RECIST with any recurrence (locoregional or distant) as well as death from any cause, whatever occurs first, will be considered as events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Death from all causes will considered as events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total toxicity burden (TTB)</measure>
    <time_frame>from randomization until 90 days after surgery</time_frame>
    <description>The combined toxicity scale TTB used in the trial by Lin et al (Lin 2020)</description>
  </other_outcome>
  <other_outcome>
    <measure>Concordance of observed pulmonary complications with predicted complications from NTCP models</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Comparison of observed and predicted toxicity rates</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood biomarkers as predictors for treatment failure</measure>
    <time_frame>up to 5 years</time_frame>
    <description>circulating tumor DNA</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients receiving adjuvant immunotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The actual number of patients starting adjuvant immunotherapy will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness of proton therapy relative to photon therapy</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Incremental cost effectiveness ratios (ICERs), cost per QALY gained, cost per complication avoided, and cost per total toxicity burden avoided will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>FDG/PET CT as predictors for treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation between diagnostic PET, planning PET-CT and PET at 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Concordance of observed cardiac complications with predicted</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Comparison of observed and predicted toxicity rates</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Radiotherapy</condition>
  <condition>Side Effect</condition>
  <condition>Proton Therapy</condition>
  <arm_group>
    <arm_group_label>Photon Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard arm with neoadjuvant chemoradiotherapy (nCXT) with photons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm with neoadjuvant chemoradiotherapy (nCPT) with protons</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon Radiotherapy</intervention_name>
    <description>nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions</description>
    <arm_group_label>Photon Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiotherapy</intervention_name>
    <description>nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions</description>
    <arm_group_label>Proton Arm</arm_group_label>
    <other_name>Proton Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically verified squamous cell carcinoma or adenocarcinoma&#xD;
             (including signet cell carcinoma and large cell carcinoma, not further specified) of&#xD;
             the esophagus (E) or gastro-esophageal junction (GEJ).&#xD;
&#xD;
               -  FDG PET/CT performed.&#xD;
&#xD;
               -  Tumor stage according to TNM (8th edition): cT1-4a and/or cN+, cM0.&#xD;
&#xD;
               -  Age ≥18 years.&#xD;
&#xD;
               -  Performance status WHO ≤2.&#xD;
&#xD;
               -  Adequate laboratory findings: hematological: hemoglobin &gt; 90 g/L, absolute&#xD;
                  neutrophil count (ANC) ≥ 1,5 x 109/L, platelets ≥ 75 x 109/L hepatic: bilirubin ≤&#xD;
                  1.5 x upper limit of normal (ULN), ALAT ≤ 3 x ULN renal: creatinine ≤ 1.5 x ULN,&#xD;
                  GFR (may be calculated) &gt; 30 ml/min&#xD;
&#xD;
               -  MDT decision on suitability to undergo curatively intended nCXT or nCPT followed&#xD;
                  by surgery.&#xD;
&#xD;
               -  Planned transthoracic esophagectomy or gastrectomy being open, minimally invasive&#xD;
                  of combination of both.&#xD;
&#xD;
               -  Ability to adhere to procedures for study and follow-up.&#xD;
&#xD;
               -  Patients with low risk cancers with a life expectancy above 5 years (e.g. low&#xD;
                  risk prostate cancer) are allowed in the study. Adequately treated diagnoses such&#xD;
                  as cervix uteri carcinoma in situ, in situ urothelial carcinoma or localized&#xD;
                  non-melanoma skin cancer are allowed, regardless of time of diagnosis.&#xD;
&#xD;
               -  Patients of childbearing potential: pregnancy prevention according to the&#xD;
                  standards of each country. Patients of childbearing potential must present a&#xD;
                  negative pregnancy test. Patients and their partners must use effective&#xD;
                  contraception. Patients of childbearing potential included in the study must use&#xD;
                  oral contraceptives, intrauterine devices, depot injection of progestin subdermal&#xD;
                  implantation, a hormonal vaginal ring, or transdermal patch during the study&#xD;
                  treatment and one month after.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet one or more of the following exclusion criteria cannot be included in the&#xD;
        study:&#xD;
&#xD;
          -  Prior thoracic XT or PT, chemotherapy or surgical resection in the esophageal/gastric&#xD;
             region (previous EMR or ESD is allowed).&#xD;
&#xD;
          -  Tumor &lt; 3 cm from oropharyngeal sphincter.&#xD;
&#xD;
          -  Planned transhiatal resection&#xD;
&#xD;
          -  Patients with other previous malignancies are excluded unless a complete remission or&#xD;
             complete resection was achieved at least 5 years prior to study entry.&#xD;
&#xD;
          -  Any unstable systemic disease (including clinically significant lung and&#xD;
             cardiovascular disease, unstable angina, New York Heart Association (NYHA) grade&#xD;
             III-IV congestive heart, severe hepatic, renal or metabolic disease or active&#xD;
             inflammatory bowel disease).&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy greater than grade 1 (scored according to CTCAE&#xD;
             v5.0).&#xD;
&#xD;
          -  Any other serious or uncontrolled illness, which, in the opinion of the investigator,&#xD;
             makes it undesirable for the patient to enter the trial.&#xD;
&#xD;
          -  Unable to understand and digest study patient information or comply with study&#xD;
             treatment and safety instructions.&#xD;
&#xD;
          -  Gastro-esophageal stent within the irradiated volume.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Nordsmark, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Haustermans, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>UKleuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorte Winter</last_name>
    <phone>+45 78456442</phone>
    <email>dorte.skriver.winther@auh.rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Toke Hansen, PhD</last_name>
    <phone>+45 78456442</phone>
    <email>tokeha@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catholic University of Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital (AUH)</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Marianne Nordsmark, Dr.</last_name>
      <email>marianne.nordsmark@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Hanna Mortensen, Dr.</last_name>
      <email>Hanna.Mortensen@auh.rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard (CLB)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne (CAL)</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme Doyen</last_name>
      <email>Jerome.DOYEN@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität Dresden (TUD)</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Nazionale di Adroterapia Oncologica (CNAO)</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Ester Orlandi</last_name>
      <email>ester.orlandi@cnao.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Provinciale Per I Servizi Sanitari (APSS)</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stichting Maastricht Radiation Oncology (MAASTRO)</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Scherrer Institute (PSI)</name>
      <address>
        <city>Villigen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien Weber</last_name>
      <email>damien.weber@psi.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital (UCLH)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS foundation trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

